Synapse - Howard Scher

Results (1130)

Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody

Journal Article

Carrasquillo, J. A.; Fine, B. M.; Pandit-Taskar, N.; Larson, S. M.; Fleming, S. E.; Fox, J. J.; Cheal, S. M.; O'Donoghue, J. A.; Ruan, S.; Ragupathi, G.; more...
Journal of Nuclear Medicine (2019)

Fulltext@MSK | Save

Comparison of magnetic resonance imaging-stratified clinical pathways and systematic transrectal ultrasound-guided biopsy pathway for the detection of clinically significant prostate cancer: A systematic review and meta-analysis of randomized controlled trials

Review

Woo, S.; Suh, C. H.; Eastham, J. A.; Zelefsky, M. J.; Morris, M. J.; Abida, W.; Scher, H. I.; Sidlow, R.; Becker, A. S.; Wibmer, A. G.; more...
European Urology Oncology (2019)

Fulltext@MSK | Save

"Was it worth it?'' as a novel, patient-centered metric of the tolerability of cancer therapy

Meeting Abstract

Thanarajasingam, G.; Basch, E.; Scher, H. I.; Bennett, A. V.; Mazza, G. L.; Schwab, G.; Weitzman, A. L.; Sloan, J. A.; Rogak, L. J.; Dueck, A. C.
Quality of Life Research (2019)

Fulltext@MSK | Save

CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts)

Meeting Abstract

Scher, H. I.; Lee, J.; Dago, A. E.; Barnett, E.; Sutton, R.; Carbone, E.; Schreiber, N. A.; Hullings, M.; Ebrahim, N.; Landers, M. A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Schonhoft, J.; Graf, R. P.; Jendrisak, A.; Barnett, E.; Jayaram, A.; Winquist, E.; Landers, M.; Wang, Y.; Allan, A. L.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes

Meeting Abstract

Mota, J. M.; Barnett, E.; Nauseef, J.; Stopsack, K. H.; Wibmer, A. G.; Danila, D. C.; Rathkopf, D. E.; Slovin, S. F.; Kantoff, P. W.; Scher, H. I.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients

Meeting Abstract

McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Paller, C. J.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W. D.; Den, R. B.; Deville, C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC)

Meeting Abstract

Autio, K. A.; Antonarakis, E. S.; Baser, R.; Stein, M. N.; Shevrin, D. H.; Vaishampayan, U. N.; Mayer, T. M.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2

Meeting Abstract

Abida, W.; Bryce, A. H.; Vogelzang, N. J.; Amato, R. J.; Percent, I. J.; Shapiro, J. D.; McDermott, R. S.; Hussain, A.; Patnaik, A.; Petrylak, D. P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma

Meeting Abstract

Teo, M. Y.; Taplin, M. E.; Eastham, J. A.; Benoliel, H.; Kibel, A. S.; McBride, S. M.; Nguyen, P. L.; Gopalan, A.; Lis, R.; Scher, H. I.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save